[Total illness costs of schizophrenia and monetary evaluation of prevention of recurrence exemplified by a standard depot neuroleptic (flupenthixol decanoate)].
Treatment of patients suffering from schizophrenia is very expensive. However, by consistently and methodically performed medical prophylaxis the disease can be controlled sufficiently well. Regular prophylactic treatment compared to repeated treatment of acute episodes has both medical advantages and reduces cost by reducing the rate of hospitalisation. Prophylactic treatment with Flupentixoldecanoat can save up to 68% of costs.
Osterheider
M
M
Westfälisches Zentrum für Psychiatrie und Psychotherapie Paderborn, Akademisches Lehrkrankenhaus der Universität Münster.
Franken-Hiep
K
K
Horn
R
R
D000328:Adult; D000368:Aged; D000553:Ambulatory Care / Q000191:economics; D017046:Cost Savings; D018492:Dopamine Antagonists / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use; D005260:Female; D005475:Flupenthixol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use; D005858:Germany; D006801:Humans; D008297:Male; D008875:Middle Aged; D010359:Patient Readmission / Q000191:economics*; D012008:Recurrence; D012559:Schizophrenia / Q000188:drug therapy / Q000191:economics*; D012565:Schizophrenic Psychology; D012943:Social Security / Q000191:economics
D018492:Dopamine Antagonists; C007761:flupenthixol decanoate; D005475:Flupenthixol
Gesamtkrankenkosten der Schizophrenie und monetäre Bewertung einer Rezidivprophylaxe am Beispiel eines Standard-Depot-Neuroleptikums (Flupentixoldecanoat).